Advertisement

Topics

Enbrel

00:33 EDT 22nd September 2017 | BioPortfolio

Technical Background

Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis have too much TNF in their bodies. ENBREL reduces levels of the active form of TNF.  Further details can be viewed:

Mechanism of Action:

ENBREL (etanercept) is grouped within a class of medications called biologic response modifiers, or biologics. By working on the immune system, biologics block proteins that contribute to the disease process. Because ENBREL suppresses the immune system, patients are at a greater risk for getting serious infections.

Enbrel (etanercept) is a soluble TNF-receptor fusion protein used for the treatment of moderate to severe active RA patients who are unresponsive to one or more DMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications including psoriasis and ankylosing spondylitis. Enbrel is a bivalent p75 receptor linked to the Fc portion of human IgG. Enbrel binds to lymphotoxin and TNF-alpha, blocking its interaction with cell surface TNF receptors, thus preventing synovial inflammation.

Indications:

ENBREL is manufactured by Immunex Corporation and marketed by Amgen Inc. and Pfizer Inc.  ENBREL is a prescription medicine that can be self-injected. It is used to treat five long-term inflammatory diseases:

  • moderate to severe rheumatoid arthritis (RA),
  • moderate to severe plaque psoriasis, psoriatic arthritis,
  • moderate to severe juvenile idiopathic arthritis (JIA), and
  • ankylosing spondylitis (AS).

Source: http://www.enbrel.com/index.jspx 
Safety information: http://www.enbrel.com/important-safety-information.jspx

For further drug information refer to: http://www.bioportfolio.com/resources/drug/21166/Enbrel.html

Market data:

The therapeutic drug class of TNF antibodies presently consists of five different approved and marketed products which all together achieved worldwide sales of more than US$ 24 bln in 2011. Among the approved indications for use of TNF antibodies in general are rheumatoid arthritis, idiopathic juvenile arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, psoriasis, ulcerative colitis and Crohn’s disease. However, not all TNF antibodies are the same and their efficacy had to be demonstrated for each indication.

ENBREL was the number two selling biotechnology product in 2011 with $7,870 million sales - Top 50 Biopharma Products 2011

Drug maker: Amgen and Pfizer8

Indication(s): Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis

2012 sales: $7.963 billion [$4.236 billion Amgen + $3.737 billion Pfizer]

 

Quick Search
Advertisement
 

review and buy Enbrel market research data and corporate reports here